Skip to main content
Search
Search
Anywhere
Quick Search anywhere
Enter words / phrases / DOI / ISBN / keywords / authors / etc
Search
Advanced Search
Login
Skip main navigation
Open Drawer Menu
Close Drawer Menu
Home
Journal of Comparative Effectiveness Research
Journal of Patient Centricity
The Evidence Base
Skip slideshow
Journal of Comparative Effectiveness Research
ISSN (print): 2042-6305 • ISSN (online): 2042-6313
Impact Factor: 2.8 (2025) • CiteScore: 4.2 (2025) • Open Access
Read more
Journal of Patient Centricity
ISSN (online): 2978-8579
In partnership with the PCSIG • Open Access
Read more
The Evidence Base
Latest news, opinion and insight into hot topics including RWE, HEOR, HTA and market access
Read more
Latest
Letter to the Editor: Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema
Irmgard Andresen
,
Natalie Khutoryansky
,
Sarah L Feeny
, and
Alissa Dangel
Journal of Comparative Effectiveness Research
19 Oct 2026
Response to Letter to the Editor regarding “Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema”
Yinglei Li
,
Simona Gavata-Steiger
,
Chiara Nenci
,
Nicolas Scheuer
,
Sarah Walsh
,
Anja Haltner
, and
Imtiaz A Samjoo
Journal of Comparative Effectiveness Research
19 Oct 2026
Event preview: 14th IMPACCT Real-World Evidence Summit
The Evidence Base
19 Oct 2026
The methods were never the problem: Mark Sculpher on politics, opportunity cost and the future of HTA
The Evidence Base
19 Oct 2026
Journal of Comparative Effectiveness Research
Open access, peer-reviewed journal offering rapid publication for all aspects of HEOR and related areas
Read More
FROM THE EVIDENCE BASE
19 Oct 2026
Event preview: 14th IMPACCT Real-World Evidence Summit
19 Oct 2026
FDA launches Rare Disease Framework Initiative to align evidence expectations for rare disease therapies
16 Oct 2026
World Orphan Drug Congress Europe 2026: Previewing the discussions on evidence, HTA and access
19 Oct 2026
The methods were never the problem: Mark Sculpher on politics, opportunity cost and the future of HTA
16 Oct 2026
World Orphan Drug Congress Europe 2026: Previewing the discussions on evidence, HTA and access
15 Oct 2026
2026 RWE4Decisions Symposium: Improving real-world evidence for HTA and reimbursement decisions
19 Oct 2026
Event preview: 14th IMPACCT Real-World Evidence Summit
19 Oct 2026
The methods were never the problem: Mark Sculpher on politics, opportunity cost and the future of HTA
12 Oct 2026
Moving the finish line for HEOR: Rob Abbott on closing the gap between science and decisions
The Evidence Base
Online hub providing the latest news, opinion and insights into HEOR, RWE, HTA and more
Read More
FROM THE EVIDENCE BASE
19 Oct 2026
Event preview: 14th IMPACCT Real-World Evidence Summit
19 Oct 2026
The methods were never the problem: Mark Sculpher on politics, opportunity cost and the future of HTA
19 Oct 2026
FDA launches Rare Disease Framework Initiative to align evidence expectations for rare disease therapies
16 Oct 2026
World Orphan Drug Congress Europe 2026: Previewing the discussions on evidence, HTA and access
.png)
.png)
